Metropolitan Life Insurance CO Immuno Gen, Inc. Transaction History

Metropolitan Life Insurance CO

  • $281 Million
  • Q3 2024

Shares

58 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$12.46 - $29.95 $4,622 - $11,111
-371 Reduced 2.65%
13,608 $403,000
Q3 2023

Nov 14, 2023
BUY
$14.09 - $19.87 $11,201 - $15,796
795 Added 6.03%
13,979 $221,000
Q2 2023

Aug 10, 2023
BUY
$3.75 - $20.05 $10,338 - $55,277
2,757 Added 26.44%
13,184 $248,000
Q1 2023

May 15, 2023
SELL
$3.67 - $4.92 $9,193 - $12,324
-2,505 Reduced 19.37%
10,427 $40,000
Q4 2022

Jun 14, 2023
BUY
$4.55 - $6.31 $11,397 - $15,806
2,505 Added 24.02%
12,932 $64.1 Million
Q3 2022

Jun 14, 2023
BUY
$4.48 - $6.47 $11,222 - $16,207
2,505 Added 24.02%
12,932 $61.8 Million
Q3 2022

Mar 30, 2023
BUY
$4.48 - $6.47 $12,266 - $17,714
2,738 Added 26.86%
12,932 $61,000
Q3 2022

Nov 14, 2022
BUY
$4.48 - $6.47 $12,266 - $17,714
2,738 Added 26.86%
12,932 $62,000
Q2 2022

Jun 20, 2023
SELL
$3.15 - $5.76 $733 - $1,342
-233 Reduced 2.23%
10,194 $45,000
Q2 2022

Mar 30, 2023
SELL
$3.15 - $5.76 $7,966 - $14,567
-2,529 Reduced 19.88%
10,194 $45,000
Q2 2022

Aug 11, 2022
SELL
$3.15 - $5.76 $7,966 - $14,567
-2,529 Reduced 19.88%
10,194 $46,000
Q1 2022

Jun 20, 2023
BUY
$4.26 - $7.48 $9,780 - $17,174
2,296 Added 22.02%
12,723 $60,000
Q1 2022

Mar 30, 2023
SELL
$4.26 - $7.48 $166,059 - $291,577
-38,981 Reduced 75.39%
12,723 $60,000
Q1 2022

May 12, 2022
SELL
$4.26 - $7.48 $166,059 - $291,577
-38,981 Reduced 75.39%
12,723 $61,000
Q4 2021

Jun 21, 2023
BUY
$4.75 - $7.5 $196,065 - $309,577
41,277 Added 395.87%
51,704 $383,000
Q4 2021

Mar 30, 2023
BUY
$4.75 - $7.5 $4,887 - $7,717
1,029 Added 2.03%
51,704 $383,000
Q4 2021

Feb 15, 2022
BUY
$4.75 - $7.5 $4,887 - $7,717
1,029 Added 2.03%
51,704 $384,000
Q3 2021

Jun 21, 2023
BUY
$5.02 - $6.59 $202,044 - $265,234
40,248 Added 386.0%
50,675 $287,000
Q3 2021

Mar 30, 2023
BUY
$5.02 - $6.59 $38,036 - $49,932
7,577 Added 17.58%
50,675 $287,000
Q3 2021

Nov 15, 2021
BUY
$5.02 - $6.59 $38,036 - $49,932
7,577 Added 17.58%
50,675 $287,000
Q2 2021

Jun 21, 2023
BUY
$5.79 - $8.6 $189,165 - $280,970
32,671 Added 313.33%
43,098 $284,000
Q2 2021

Mar 30, 2023
SELL
$5.79 - $8.6 $33,553 - $49,837
-5,795 Reduced 11.85%
43,098 $284,000
Q2 2021

Aug 16, 2021
BUY
$5.79 - $8.6 $249,253 - $370,221
43,049 Added 87855.1%
43,098 $284,000
Q1 2021

Jun 26, 2023
BUY
$6.5 - $10.53 $250,029 - $405,046
38,466 Added 368.91%
48,893 $396 Million
Q1 2021

Mar 30, 2023
SELL
$6.5 - $10.53 $13,793 - $22,344
-2,122 Reduced 4.16%
48,893 $396,000
Q1 2021

May 14, 2021
SELL
$6.5 - $10.53 $331,279 - $536,671
-50,966 Reduced 99.9%
49 $396,000
Q4 2020

Jun 22, 2023
BUY
$3.7 - $7.66 $150,175 - $310,904
40,588 Added 389.26%
51,015 $329,000
Q4 2020

Mar 30, 2023
BUY
$3.7 - $7.66 $31,956 - $66,159
8,637 Added 20.38%
51,015 $329,000
Q4 2020

Feb 16, 2021
BUY
$3.7 - $7.66 $31,956 - $66,159
8,637 Added 20.38%
51,015 $329,000
Q3 2020

Jun 26, 2023
BUY
$3.45 - $4.89 $110,230 - $156,240
31,951 Added 306.43%
42,378 $152,000
Q3 2020

Mar 30, 2023
SELL
$3.45 - $4.89 $42,255 - $59,892
-12,248 Reduced 22.42%
42,378 $152,000
Q3 2020

Nov 13, 2020
SELL
$3.45 - $4.89 $42,255 - $59,892
-12,248 Reduced 22.42%
42,378 $153,000
Q2 2020

Jun 26, 2023
BUY
$3.32 - $5.34 $146,740 - $236,022
44,199 Added 423.89%
54,626 $251,000
Q2 2020

Mar 30, 2023
BUY
$3.32 - $5.34 $5,992 - $9,638
1,805 Added 3.42%
54,626 $251,000
Q2 2020

Aug 14, 2020
BUY
$3.32 - $5.34 $5,992 - $9,638
1,805 Added 3.42%
54,626 $251,000
Q1 2020

Jul 12, 2023
BUY
$2.12 - $6.8 $93,822 - $300,940
44,256 Added 424.44%
54,683 $186,000
Q1 2020

Mar 30, 2023
BUY
$2.12 - $6.8 $13,716 - $43,996
6,470 Added 13.96%
52,821 $180,000
Q1 2020

May 15, 2020
BUY
$2.12 - $6.8 $13,716 - $43,996
6,470 Added 13.96%
52,821 $180,000
Q4 2019

Jul 12, 2023
BUY
$2.25 - $5.8 $80,829 - $208,359
35,924 Added 344.53%
46,351 $236,000
Q4 2019

Mar 30, 2023
SELL
$2.25 - $5.8 $5,283 - $13,618
-2,348 Reduced 4.82%
46,351 $236,000
Q4 2019

Feb 14, 2020
SELL
$2.25 - $5.8 $5,283 - $13,618
-2,348 Reduced 4.82%
46,351 $237,000
Q3 2019

Jul 12, 2023
BUY
$2.22 - $3.39 $84,963 - $129,742
38,272 Added 367.05%
48,699 $117,000
Q3 2019

Mar 30, 2023
BUY
$2.22 - $3.39 $16,268 - $24,841
7,328 Added 17.71%
48,699 $117,000
Q3 2019

Nov 14, 2019
BUY
$2.22 - $3.39 $16,268 - $24,841
7,328 Added 17.71%
48,699 $118,000
Q2 2019

Jul 12, 2023
BUY
$1.8 - $3.3 $68,889 - $126,297
38,272 Added 367.05%
48,699 $105,000
Q1 2019

Jul 13, 2023
BUY
$2.41 - $5.91 $74,575 - $182,879
30,944 Added 296.77%
41,371 $112,000
Q1 2019

Mar 30, 2023
BUY
$2.41 - $5.91 $68,537 - $168,074
28,439 Added 219.91%
41,371 $112,000
Q1 2019

May 16, 2019
BUY
$2.41 - $5.91 $91,457 - $224,278
37,949 Added 1108.97%
41,371 $112,000
Q1 2019

May 15, 2019
SELL
$2.41 - $5.91 $105,063 - $257,646
-43,595 Reduced 92.72%
3,422 $1.17 Million
Q4 2018

Jul 13, 2023
BUY
$3.94 - $9.7 $144,164 - $354,923
36,590 Added 350.92%
47,017 $225,000
Q4 2018

Feb 14, 2019
BUY
$3.94 - $9.7 $144,676 - $356,184
36,720 Added 356.61%
47,017 $226,000
Q3 2018

Jul 13, 2023
BUY
$8.6 - $11.26 $314,674 - $412,003
36,590 Added 350.92%
47,017 $445 Million
Q3 2018

Nov 14, 2018
SELL
$8.6 - $11.26 $274,305 - $359,148
-31,896 Reduced 75.6%
10,297 $98,000
Q2 2018

Aug 15, 2018
BUY
$9.52 - $12.15 $81,329 - $103,797
8,543 Added 25.39%
42,193 $0
Q1 2018

May 15, 2018
BUY
$6.7 - $12.95 $23,798 - $45,998
3,552 Added 11.8%
33,650 $0
Q4 2017

Feb 15, 2018
SELL
$5.07 - $7.92 $180,390 - $281,793
-35,580 Reduced 54.17%
30,098 $193,000
Q3 2017

Nov 14, 2017
SELL
$5.4 - $8.47 $4,530 - $7,106
-839 Reduced 1.26%
65,678 $502,000
Q2 2017

Aug 14, 2017
BUY
N/A
66,517
66,517 $473,000

Others Institutions Holding IMGN

# of Institutions
8
Shares Held
1.41M
Call Options Held
0
Put Options Held
0
View Full List

About ImmunoGen, Inc.

IMGN Quotes by TradingView
  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email